XSpray Pharma (Sweden) Analysis

XSpray Stock Analysis Notes

About 47.0% of the company outstanding shares are owned by insiders. The book value of XSpray Pharma was at this time reported as 24.95. The company recorded a loss per share of 5.18. XSpray Pharma AB had not issued any dividends in recent years. Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden. For more information please call the company at 46 87 30 37 00 or visit https://www.xspraypharma.com.

XSpray Pharma AB Investment Alerts

XSpray Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate XSpray Pharma's market, we take the total number of its shares issued and multiply it by XSpray Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Technical Drivers

As of the 20th of July, XSpray Pharma maintains the Market Risk Adjusted Performance of 1.76, mean deviation of 3.29, and Downside Deviation of 3.44. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of XSpray Pharma AB, as well as the relationship between them.

XSpray Pharma AB Price Movement Analysis

XSpray Pharma Outstanding Bonds

XSpray Pharma Predictive Daily Indicators

XSpray Pharma Forecast Models

XSpray Pharma's time-series forecasting models are one of many XSpray Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XSpray Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how XSpray Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling XSpray shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as XSpray Pharma. By using and applying XSpray Stock analysis, traders can create a robust methodology for identifying XSpray entry and exit points for their positions.

When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.